Aeras Market Share Analysis for November 2025

Health > Health Conditions and Concerns

Domainaeras.org

Year Founded2003

Employees51 - 200

Annual Revenue$5M - $10M

Aeras

Aeras (including company regionals)

aeras.org

See more website traffic and engagement information

Aeras Revenue up to November 2025 is 5M - 10M

revenue generated by Aeras top domains

Aeras top domains revenue over 3 years

Revenue for Aeras top domains

aeras.org5M - 10M

See more with Sales Intelligence

Total visits to Aeras's top domains

Understand Aeras market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Aeras's top domains

Analyze Aeras engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Aeras's top domains

See how Aeras keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Aeras top competitors by domain

Top similar sites in November 2025, ranked by their affinity

vbivaccines.comCompany NameVBI VaccinesEmployees51 - 200HQUnited States, Massachusetts, CambridgeAnnual revenue< $1MTotal visits5.9KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Aeras

These are the website technologies, by industry, used by Aeras top domains

Social (4)

Facebook Connect

Mobile (3)

Meta Viewport

Audio Video Media (2)

YouTube

Comments System (2)

Disqus

More Technologies

3

See all

News & Signals from Aeras

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsAeras sold assets to International AIDS Vaccine Initiative, Inc. on Feb 7th '22.In addition, IAVI recently acquired the clinical assets of AERAS, a non-profit similar to IAVI, which has been working to develop vaccines for TB.

NewsAeras hired Danilo Casimiro as Executive Director in the Department of Infectious Diseases and Vaccine Research on Feb 29th '16.Aeras today announced that Danilo Casimiro, Ph.D., has joined the organization as Chief Scientific Officer (CSO) effective February 29.